In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The Food and Drug Administration ended 2024 with a quartet of notable drug approvals, including three of new medicines that Vertex Pharmaceuticals, Novo Nordisk and Bristol Myers Squibb developed for ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Industry experts said profit pressure and M&A contributed to job losses. They said layoffs will likely persist in 2025, but ...